Information Technology · Electronic Computers

OMCL OMNICELL, INC. SEC Filings & Insider Trading Activity 2026

company
CIK 926326109 filings
Russell 2000

OMCL at a glance

OMNICELL, INC. (OMCL, SEC CIK 926326) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on October 29, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), OMNICELL, INC. (OMCL) reported revenue of $1.2 billion (up 6.5% from FY2024) and net income of $2.1 million. Diluted EPS was $0.04.
  • As of September 30, 2026, 31 institutional investment managers tracked by SignalX reported holding OMNICELL, INC. (OMCL) shares worth $876.6 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Njoku Nnamdi on November 16, 2026 of 3,083 shares at $35.00 per share.
  • In the last 90 days, OMCL insiders reported 0 open-market purchases ($0) and 1 open-market sale ($108K) on Form 4, a net sale of $108K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$1.2B
+6.5% vs prior year
Insiders · 90 days
0 buys · 1 sell
Net −$108K
13F holders
31 funds
$876.6M · −1 vs prior quarter
Latest 8-K
Oct 29, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: medication management solutions and adherence tools primarily for healthcare systems and pharmacies in the U.S. market
  • No new product lines or segments introduced; company continues managing as a single operating and reporting segment
  • Strategic focus remains on integrated hardware, software, and services contracts with emphasis on identifying distinct performance obligations for revenue recognition
  • Revenue $1.185B, up 6.5% YoY driven by product revenues $665.7M (+5.6%) and service revenues $519.1M (+7.8%)
  • Noteworthy: net income sharply decreased to $2.1M from $12.5M in prior year, reflecting narrowed operating income $5.2M vs $0.3M prior and ongoing investment in R&D ($88.7M)

Risk Factors

  • Regulatory risk under privacy and data protection laws with potential compliance cost and liability exposure
  • Cybersecurity disruption risk involving information system breaches impacting business operations
  • Third-party service provider dependency creating information security vulnerabilities from cloud and cybersecurity vendors
  • Key-person risk from reliance on Chief Information Security Officer with 20+ years experience overseeing cybersecurity
  • Audit Committee oversight risk with reliance on post-incident remediation and monitoring to mitigate cybersecurity incidents

Management Discussion & Analysis

  • Revenue $1.185B in 2025, up $72.6M or 7% YoY from $1.112B in 2024; product revenues $665.7M (+6%), service revenues $519.1M (+8%)
  • ARR $636M in 2025, up from $580M in 2024; product bookings $535M in 2025, down from $558M in 2024
  • Operating segment: Single reporting segment; best performing area includes XTExtend product revenue growth; worst impacted includes XT Series dispensing systems due to lifecycle timing and Central Pharmacy Dispensing Service product revenue decline
  • No segment-level profitability or margin % given; CODM evaluates consolidated net income (loss)
  • Forward outlook: Anticipates healthcare fiscal headwinds including $910B Medicaid cut, rising tariffs, and labor shortages pressuring margins; expects shift to flexible payment models (leasing, subscriptions) and investment in pharmacy automation and analytics

AI summary of the OMCL 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $307.9M, down $2.8M, or 1% YoY, with product revenue down 3% to $173.1M
  • Gross margin 45% vs 43% YoY, driven by lower service costs, partially offset by higher semiconductor costs
  • Best line: service revenue up 1% to $134.8M, led by Specialty Pharmacy Services; worst: product revenue down 3%
  • Cash $314.9M vs $196.5M at December 31, 2025; operating cash flow $155.9M for nine months
  • Outlook: tariffs, labor shortages, healthcare policy changes, and Medicaid spending reductions creating margin and demand headwinds

Risk Factors

  • No material changes to previously disclosed risk factors in the December 31, 2025 Form 10-K
  • Regulatory and compliance exposure remains a significant carried-forward risk
  • Healthcare technology competition remains a key operational risk
  • Customer concentration remains a potential market risk
  • Liquidity and debt obligations remain carried-forward financial risks

AI summary of the OMCL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 29, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 results for quarter ended September 30, 2026 announced on October 29, 2026
  • Full-year 2026 guidance updated, potentially affecting valuation and investor expectations

Item EX-99.1: Item EX-99.1

  • Q3 revenue $308M, down 1% year over year, but profitability exceeded the high end of prior guidance
  • GAAP EPS $0.24 versus $0.12, while non-GAAP EPS rose to $0.58 from $0.51
Filed Jul 30, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 revenue $312M, up 7% year over year; connected devices, SaaS, Expert Services, and technical services drove growth
  • GAAP net income rose to $24M from $6M; non-GAAP EPS increased to $0.94 from $0.45

Item 2.02: Results of Operations and Financial Condition

  • Press release covers quarterly results for the period ended June 30, 2026
  • Updated full-year 2026 guidance, a potentially market-moving outlook revision
Filed Jul 1, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Nnamdi Njoku appointed President effective July 1, 2026, while retaining COO responsibilities
  • Randall Lipps remains CEO and Chairman, refocusing on strategic relationships, solution portfolio evolution, and long-term vision

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Nnamdi Njoku appointed President effective July 1, 2026, retaining Chief Operating Officer responsibilities
  • Randall Lipps relinquished President role but remains CEO and Board Chairman, preserving leadership continuity

AI summaries of OMCL 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for OMCL

Don't miss the next OMCL filing

  • Alerts as it files. A push when OMCL files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut OMCL, by share count.
  • Ask anything. An AI agent that reads every OMCL filing and answers with sources.

OMCL alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Njoku NnamdiSellNov 16, 2026$35.00
NUTT BRIAN H.FNov 15, 2026$35.03
Manley Corey JFNov 15, 2026$35.03
LIPPS RANDALL AFNov 15, 2026$35.03
Radford Harlan BairdFNov 15, 2026$35.03
Njoku NnamdiFNov 15, 2026$35.03
Njoku NnamdiSellAug 17, 2026$36.85
Manley Corey JFAug 15, 2026$37.30

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$1.1B$1.2B
Gross Profit-$471.0M$503.4M
Operating Income-$337K$5.2M
Net Income-$12.5M$2.1M
Gross Margin-42.3%42.5%
Op. Margin-0.0%0.4%
Net Margin-1.1%0.2%
Balance Sheet
Total Assets$2.2B$2.1B$2.0B
Equity$1.2B$1.2B$1.2B
ROE-1.0%0.2%
Per Share
EPS-$0.27$0.04
Cash Flow
Operating CF-$187.7M$127.3M
CapEx-$36.5M$40.4M

Source: XBRL data in OMNICELL, INC. (OMCL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate OMCL share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
OMCL shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202631$876.6M
Q2 202632$1.08B
Q1 202629$849.5M
Q4 202528$1.15B
Q3 202529$770.9M
Q2 202528$724.8M
Q1 202526$559.6M
Q4 202424$628.9M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 227 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

OMCL filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
10-QNov 4, 2026Analysis
8-KOct 29, 2026Analysis-
4Aug 18, 2026--
4Aug 18, 2026--
4Aug 18, 2026--
4Aug 18, 2026--
10-QAug 5, 2026Analysis
8-KJul 30, 2026Analysis-
4Jul 17, 2026--
4Jul 6, 2026--
8-KJul 1, 2026Analysis-
4Jun 3, 2026-
4Jun 3, 2026-
4Jun 3, 2026-
4Jun 3, 2026-
4Jun 3, 2026-
4Jun 3, 2026-
4Jun 3, 2026-
4Jun 3, 2026-
8-KMay 26, 2026Analysis

Related Information Technology companies

All Information Technology →

OMCL SEC filings: frequently asked questions

Are OMCL insiders buying or selling?

In the last 90 days, OMNICELL, INC. (OMCL) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $107,905 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold OMCL stock?

As of September 30, 2026, the largest OMNICELL, INC. (OMCL) holders among the 13F filers tracked by SignalX were BlackRock ($262.7 million), Vanguard Portfolio Management LLC ($107.7 million), Dimensional Fund Advisors ($87.1 million), State Street Corp ($71.2 million), Vanguard Capital Management LLC ($66.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was OMCL's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), OMNICELL, INC. (OMCL) reported revenue of $1.2 billion (up 6.5% from FY2024) and net income of $2.1 million. Diluted EPS was $0.04. The figures come from the XBRL data in the 10-K.

What are the main risks in OMCL's latest 10-K?

In the 10-K filed February 26, 2026, OMNICELL, INC. (OMCL) flagged: Regulatory risk under privacy and data protection laws with potential compliance cost and liability exposure. Cybersecurity disruption risk involving information system breaches impacting business operations. (AI summary of the Risk Factors section.)

What did OMCL report in its latest 8-K?

OMNICELL, INC. (OMCL) filed an 8-K on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 results for quarter ended September 30, 2026 announced on October 29, 2026.

What are the latest OMCL SEC filings?

OMNICELL, INC. (OMCL) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on October 29, 2026 and a Form 4 insider filing on November 17, 2026.

What is OMCL's SEC CIK number?

OMNICELL, INC. (OMCL)'s SEC Central Index Key (CIK) is 926326. EDGAR lists every OMCL filing under that number.

Ask anything about OMCL

The research agent reads OMCL's filings, financials, insider trades and 13F holders, then answers with sources.